Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Cooper DA, et al. Among authors: clumeck n. J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697. J Infect Dis. 2010. PMID: 20151839 Clinical Trial.
A controlled trial of zidovudine in primary human immunodeficiency virus infection.
Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L, et al. Kinloch-De Loës S, et al. Among authors: clumeck n. N Engl J Med. 1995 Aug 17;333(7):408-13. doi: 10.1056/NEJM199508173330702. N Engl J Med. 1995. PMID: 7616989 Free article. Clinical Trial.
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
Mulder JW, Cooper DA, Mathiesen L, Sandström E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM, et al. Mulder JW, et al. Among authors: clumeck n. AIDS. 1994 Mar;8(3):313-21. doi: 10.1097/00002030-199403000-00004. AIDS. 1994. PMID: 7913326 Clinical Trial.
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W, Clumeck N, Faber V, Stille W, Hirschel B, et al. Cooper DA, et al. Among authors: clumeck n. AIDS. 1993 Feb;7(2):197-207. doi: 10.1097/00002030-199302000-00007. AIDS. 1993. PMID: 8096703 Clinical Trial.
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, et al. Cooper DA, et al. Among authors: clumeck n. N Engl J Med. 1993 Jul 29;329(5):297-303. doi: 10.1056/NEJM199307293290501. N Engl J Med. 1993. PMID: 8100611 Free article. Clinical Trial.
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD; MaxCmin1 Trial Group. Dragsted UB, et al. Among authors: clumeck n. J Infect Dis. 2003 Sep 1;188(5):635-42. doi: 10.1086/377288. Epub 2003 Aug 20. J Infect Dis. 2003. PMID: 12934178 Clinical Trial.
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. Hoen B, et al. Among authors: clumeck n. Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319 Free article.
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT. Opravil M, et al. Among authors: clumeck n. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49. doi: 10.1097/QAI.0b013e31815ac47d. J Acquir Immune Defic Syndr. 2008. PMID: 18156990 Clinical Trial.
377 results